A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Registration Number
- NCT01351415
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This open-label, randomized, multicenter study will evaluate the efficacy and safety of bevacizumab (Avastin) in combination with standard of care (SOC) treatment in participants with advanced non-squamous NSCLC. Participants will be enrolled at documentation of progression of disease (PD) after 4-6 cycles of first-line treatment with bevacizumab plus a platinum doublet-containing therapy and a minimum of two cycles of bevacizumab maintenance treatment prior to PD. Participants will be randomly assigned to one of two treatment arms to receive either bevacizumab plus SOC treatment or SOC treatment alone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 485
- Histologically or cytologically confirmed non-squamous NSCLC
- Documented progression of disease (locally recurrent or metastatic) per investigator assessment following first-line treatment with 4-6 cycles of Bevacizumab plus a platinum doublet-containing chemotherapy regimen and a minimum of 2 cycles of Bevacizumab (monotherapy) maintenance treatment prior to first progression of disease
- No treatment interruption of Bevacizumab treatment greater than 2 consecutive cycles (42 days) between the start of first-line treatment to start of Cycle 1 of second line treatment
- Randomization within 4 weeks of progression of disease
- At least one unidimensionally measurable lesion meeting RECIST v1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Participants with adequate hematological, liver, and renal function
- Female participants must not be pregnant or breast-feeding. Female participants of childbearing potential and fertile male participants must agree to use a highly effective contraceptive during the trial and for a period of at least 6 months following the last administration of trial drug(s)
- Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component
- Epidermal growth factor receptor (EGFR)-mutation-positive disease according to local laboratory testing
- History of hemoptysis greater than or equal to (>/=) grade 2 within 3 months of randomization
- History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding and active gastrointestinal bleeding
- Major cardiac disease
- Treatment with any other investigational agent within 28 days prior to randomization
- Known hypersensitivity to bevacizumab or any of its excipients, or any SOC drugs foreseen
- Malignancy other than NSCLC within 5 years prior to randomization and evidence of any other disease that contraindicates the use of an investigational or SOC drug
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Standard of Care Erlotinib Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first). Standard of Care Pemetrexed Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first). Bevacizumab + Standard of Care Bevacizumab Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first). Bevacizumab + Standard of Care Pemetrexed Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first). Bevacizumab + Standard of Care Docetaxel Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first). Bevacizumab + Standard of Care Erlotinib Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first). Standard of Care Docetaxel Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
- Primary Outcome Measures
Name Time Method Overall Survival (OS) Up to data cut-off date 24 June 2016 (approximately 5 years) Overall survival (OS) was defined as the time from the date of randomization at first progression of disease to the date of death, regardless of the cause of death.
- Secondary Outcome Measures
Name Time Method Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Up to data cut-off date 24 June 2016 (approximately 5 years) PFS was defined as the time from start of treatment to the first event of death or PD. Tumor response was assessed by the IRF according to RECIST v1.1. Disease progression or PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PFS2 is defined as the time between randomization at PD1 and the date of PD2 or death, whichever occurs first. PFS3 is defined as the time between PD2 and the date of PD3 or death, whichever occurs first.
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Up to data cut-off date 24 June 2016 (approximately 5 years) An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.
Percentage of Participants With Objective Response According to RECIST v1.1 Up to data cut-off date 24 June 2016 (approximately 5 years) The objective response is defined as complete response (CR) or partial response (PR) assessed according to the RECIST v.1.1 criteria with baseline tumour assessment as the reference. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as greater than or equal to (≥) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR.
Time to Progression (TTP) According to RECIST v1.1 Up to data cut-off date 24 June 2016 (approximately 5 years) The time to progression was defined as the time from baseline until disease progression as determined by the RECIST v1.1. TTP2 is defined as the interval between the day of randomization at PD1 and PD2. TTP3 is defined as the interval between the day of PD2 and PD3. PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Percentage of Participants Who Are Alive at Month 6, 12, and 18 Month 6, 12, 18 Percentage of participants who were alive at Month 6, 12 and 18 were reported.
Percentage of Participants With Disease Control According to RECIST v1.1 Up to data cut-off date 24 June 2016 (approximately 5 years) The disease control rate is defined as CR or PR or stable disease (SD) assessed according to the RECIST v.1.1 criteria with baseline tumour assessment as the reference. SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started for target lesions and the persistence of 1 or more non-target lesions.
Duration of Response (DoR) According to RECIST v1.1 Up to data cut-off date 24 June 2016 (approximately 5 years) Duration of response is defined as the time that measurement criteria are met for objective response (CR/PR) (whichever status is recorded first) until the first date of progression or death is documented. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than \< 10 mm. PR was defined as greater than or equal to ≥30 % decrease in sum of longest diameter of target lesions in reference to baseline sum longest diameter.
Trial Locations
- Locations (179)
University of Pennsylvania; Radiation Oncology
🇺🇸Philadelphia, Pennsylvania, United States
Miyagi Cancer Center; Respiratory Medicine
🇯🇵Miyagi, Japan
USA Mitchell Cancer Institute
🇺🇸Mobile, Alabama, United States
Palo Verde Hema/Onc
🇺🇸Glendale, Arizona, United States
Arizona Center for Cancer Care
🇺🇸Glendale, Arizona, United States
Clopton Clinic
🇺🇸Jonesboro, Arkansas, United States
California Cancer Associates for Research & Excellence, Inc.
🇺🇸Encinitas, California, United States
East Valley Hematology ; Oncology Medical Group
🇺🇸Burbank, California, United States
Scripps Clinic; Hematology & Oncology
🇺🇸La Jolla, California, United States
Coastal Integrative Cancer Care
🇺🇸San Luis Obispo, California, United States
The Hospital of Central CT
🇺🇸New Britain, Connecticut, United States
Innovative Clinical Research Institute
🇺🇸Whittier, California, United States
Eastern Ct Hema/Onco Assoc; Dept of Oncology
🇺🇸Norwich, Connecticut, United States
Baptist - MD Anderson Cancer Center
🇺🇸Jacksonville, Florida, United States
Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)
🇺🇸Jacksonville, Florida, United States
Lynn Cancer Institute - West
🇺🇸Boca Raton, Florida, United States
Mount Sinai Medical Center
🇺🇸Miami Beach, Florida, United States
Cancer Care Centers of Brevard
🇺🇸Rockledge, Florida, United States
Emory Univ Winship Cancer Inst
🇺🇸Atlanta, Georgia, United States
Summit Cancer Care PC
🇺🇸Savannah, Georgia, United States
Joliet Oncology Hematology Associates, Ltd.
🇺🇸Joliet, Illinois, United States
Kootenai Cancer Center
🇺🇸Post Falls, Idaho, United States
Alexian Brothers Neurosci Inst
🇺🇸Elk Grove Village, Illinois, United States
Oncology-Evanston Nthwest Healthcare Kellogg Cancer Care Ctr
🇺🇸Evanston, Illinois, United States
Cancer Care & Hematology; Specialists of Chicagoland
🇺🇸Niles, Illinois, United States
W. Suburban Ctr for Cncer Care
🇺🇸River Forest, Illinois, United States
Oncology Hematology Associates of Southwest Indiana
🇺🇸Newburgh, Indiana, United States
McFarland Clinic
🇺🇸Ames, Iowa, United States
University of Kentucky Medical Center
🇺🇸Lexington, Kentucky, United States
Hematology/Oncology Clinic, LLP
🇺🇸Baton Rouge, Louisiana, United States
New England Cancer Specialists
🇺🇸Scarborough, Maine, United States
Louisiana Oncology Associates
🇺🇸Lafayette, Louisiana, United States
York Hospital
🇺🇸York, Maine, United States
Anne Arundel Health System Research Instit-Annapolis Oncology Ctr
🇺🇸Annapolis, Maryland, United States
Cancer & Hematology Center of West Michigan
🇺🇸Grand Rapids, Michigan, United States
Heartland CCOP/Missouri Baptist Medical Center
🇺🇸Saint Louis, Missouri, United States
Metro-Minnesota CCOP
🇺🇸Saint Louis Park, Minnesota, United States
St Joseph Oncology
🇺🇸Saint Joseph, Missouri, United States
Stony Brook Univ Cancer Ctr; Medical Oncology Clinic
🇺🇸Stony Brook, New York, United States
Carolina Oncology Specialists, PA - Hickory
🇺🇸Hickory, North Carolina, United States
Aultman Hospital
🇺🇸Canton, Ohio, United States
Toledo Hospital; CCOP Toledo
🇺🇸Toledo, Ohio, United States
Dayton Clinical Oncology Prog
🇺🇸Dayton, Ohio, United States
Signal Point Clinical; Research Center, LLC
🇺🇸Middletown, Ohio, United States
St. Lukes Hospital and Health Network
🇺🇸Bethlehem, Pennsylvania, United States
Hematology & Oncology Assoc; North Eastern Pennsylvania
🇺🇸Dunmore, Pennsylvania, United States
St. Mary Medical Center
🇺🇸Langhorne, Pennsylvania, United States
University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Temple University Hospital
🇺🇸Philadelphia, Pennsylvania, United States
Lankenau Hospital
🇺🇸Wynnewood, Pennsylvania, United States
Memorial Hospital of Rhode Island
🇺🇸Pawtucket, Rhode Island, United States
West Clinic
🇺🇸Germantown, Tennessee, United States
University of Tennessee Medical Center Cancer Institute
🇺🇸Knoxville, Tennessee, United States
Unv of TX SW Med Cntr; Hematology/Onc
🇺🇸Dallas, Texas, United States
Delta Hematology/ Oncology Associates
🇺🇸Portsmouth, Virginia, United States
Blue Ridge Cancer Care - Roanoke
🇺🇸Roanoke, Virginia, United States
Medical Oncology Associates
🇺🇸Spokane, Washington, United States
Fox Valley Hema and Onc SC
🇺🇸Appleton, Wisconsin, United States
Gundersen Lutheran
🇺🇸La Crosse, Wisconsin, United States
UNI OF WISCONSIN SCHOOL OF MEDICINE; GI Oncology Research Group, Paul P Carbone Cancer Center
🇺🇸Madison, Wisconsin, United States
Inst. Alexander Fleming; Oncology Dept
🇦🇷Buenos Aires, Argentina
Centro Oncologico Infinito; Oncologia
🇦🇷La Pampa, Argentina
Hospital Privado de Comunidad; Oncology
🇦🇷Mar Del Plata, Argentina
ISIS Clinica Especializada
🇦🇷Santa Fe, Argentina
Sanatorio Parque de Rosario
🇦🇷Rosario, Argentina
Clínica Viedma
🇦🇷Viedma, Rio Negro, Argentina
LKH Hohenems; Abteilung für Pulmologie
🇦🇹Hohenems, Austria
Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie
🇦🇹Innsbruck, Austria
Lkh Natters; Abt. Für Atemwegs- & Lungenkrankheiten
🇦🇹Natters, Austria
A.Ö. LKH; Abt. für Lungenkrankheiten
🇦🇹Steyr, Austria
Klinikum Wels-Grieskirchen; Lungenabt.
🇦🇹Wels, Austria
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
🇦🇹Wien, Austria
Krankenhaus Der Stadt Wien Lainz; V. Medizinische Abt.
🇦🇹Wien, Austria
Clin. Europe (Ste Elisabeth)
🇧🇪Bruxelles, Belgium
SMZ - Baumgartner Hohe, Pavilion Leopold; 1.Interne Lungenabteilung, Onkologische Tagesklinik
🇦🇹Wien, Austria
Nucleo de Oncologia da Bahia - NOB
🇧🇷Salvador, Bahia, BA, Brazil
Centro de Pesquisa Clínica- Instituto do Câncer do Ceará- ICC
🇧🇷Fortaleza, CE, Brazil
Centro de Estudos e Pesquisas Oncologicas - CESPO
🇧🇷Brasilia, DF, Brazil
Sociedade beneficente de senhoras Hospital Sirio Libanes
🇧🇷Brasilia, DF, Brazil
Instituto de Câncer de Brasília
🇧🇷Taguatinga, DF, Brazil
Clinicas Oncologicas Integradas - COI
🇧🇷Rio de Janeiro, RJ, Brazil
Hospital de Caridade de Ijui; Oncologia
🇧🇷Ijui, RS, Brazil
Hospital A. C. Camargo; Oncologia
🇧🇷Sao Paulo, SP, Brazil
Clinica de Neoplasias Litoral
🇧🇷Itajai, SC, Brazil
Poly Parc Rambot La Provencale; Chimiotherapie Ambulatoire
🇫🇷Aix En Provence, France
Centre Francois Baclesse; Oncologie
🇫🇷Caen, France
Hopital Nord Ouest;Unite 2c
🇫🇷Gleize, France
Centre Hospitalier Intercommunal; Service de Pneumologie
🇫🇷Creteil, France
Centre Oscar Lambret
🇫🇷Lille, France
Hopital Calmette; Pneumologie
🇫🇷Lille, France
Hôpital Saint Joseph; Oncologie Medicale
🇫🇷Marseille, France
Hopital Louis Pradel; Cardiologie B
🇫🇷Lyon, France
Hopital Nord; Service d'Oncologie Multidisciplinaire et Innovation Thérapeutique
🇫🇷Marseille, France
Centre Antoine Lacassagne
🇫🇷Nice, France
CH Rene Dubos; Oncologie
🇫🇷Pontoise, France
Ch Lyon Sud; Chir Onc Gyne Sct Jules Courmont
🇫🇷Pierre Benite, France
Ico Rene Gauducheau; Oncologie
🇫🇷Saint Herblain, France
Institut de Cancérologie de Loire
🇫🇷St-Priest-En-Jarez, France
Centre Paul Strauss; Oncologie Medicale
🇫🇷Strasbourg, France
Hia Sainte Anne; Pneumologie
🇫🇷Toulon, France
Hopital Sainte Musse; Pneumologie
🇫🇷Toulon, France
Praxis Dr. med. David Borquez
🇩🇪Bergisch Gladbach, Germany
Chi De La Haute Saone De Vesoul; Pneumologie
🇫🇷Vesoul, France
Clinique Pasteur; Pneumologie
🇫🇷Toulouse, France
Zentralklinik Bad Berka GmbH; Pneumologie
🇩🇪Bad Berka, Germany
Klinikum Esslingen; Klinik für Kardiologie, Angiologie und Pneumologie
🇩🇪Esslingen, Germany
LungenClinic Großhansdorf
🇩🇪Großhansdorf, Germany
Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie
🇩🇪Frankfurt, Germany
Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin I
🇩🇪Halle (Saale), Germany
SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie
🇩🇪Gera, Germany
Universitaetsklinikum des Saarlandes; Innere Medizin V
🇩🇪Homburg/Saar, Germany
St. Vincentius Kliniken Karlsruhe; Abteilung Hämatologie / Onkologie
🇩🇪Karlsruhe, Germany
Fachklinik für Lungenerkrankungen
🇩🇪Immenhausen, Germany
Robert-Koch-Klinik; Pneumologie
🇩🇪Leipzig, Germany
Praxis Christian Geßner
🇩🇪Leipzig, Germany
Johannes-Wesling-Klinikum Minden; Onkologische Ambulanz / Tagesklinik
🇩🇪Minden, Germany
Ludwig-Maximilians Uni Klinik Innenstadt; Medizinische Klinik
🇩🇪Muenchen, Germany
Sotiria Hospital
🇬🇷Athens, Greece
Pius-Hospital; Klinik fuer Haematologie und Onkologie
🇩🇪Oldenburg, Germany
Metropolitan Hospital; 2Nd Oncology Clinic
🇬🇷Piraeus, Greece
General Hospital of Thessaloniki Papanikolaou; Uni Pneumonology Dept.
🇬🇷Thessaloniki, Greece
Citta Ospedaliera; Divisione Oncologia Medica
🇮🇹Avellino, Campania, Italy
IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica A
🇮🇹Napoli, Campania, Italy
Diavalkaniko Hospital
🇬🇷Thessaloniki, Greece
Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica
🇮🇹Roma, Lazio, Italy
Azienda Ospedaliera San Camillo Forlanini; U.O.C. Pneumologia Ad Indirizzo Oncologico 1
🇮🇹Roma, Lazio, Italy
IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A
🇮🇹Genova, Liguria, Italy
Az. Osp. Di Busto P.O. Di Saronno; U.O. Di Oncologia Medica
🇮🇹Saronno, Lombardia, Italy
National Cancer Center Hospital East; Thoracic Oncology
🇯🇵Chiba, Japan
A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii
🇮🇹Pisa, Toscana, Italy
Aichi Cancer Center Hospital; Respiratory Medicine
🇯🇵Aichi, Japan
National Hospital Organization Shikoku Cancer Center; Thoracic Oncology
🇯🇵Ehime, Japan
National Hospital Organization Kyushu Cancer Center, Thoracic Oncology
🇯🇵Fukuoka, Japan
Hyogo Cancer Center; Thoracic Oncology
🇯🇵Hyogo, Japan
Yokohama Municipal Citizen'S Hospital; Respiratory
🇯🇵Kanagawa, Japan
Kanagawa Cardiovascular and Respiratory Center; Respiratory Medicine
🇯🇵Kanagawa, Japan
Okayama University Hospital; Respiratory and Allergy Medicine
🇯🇵Okayama, Japan
OSAKA CITY GENERAL HOSPITAL;Medical Oncology
🇯🇵Osaka, Japan
Osaka International Cancer Institute; Thoracic Oncology
🇯🇵Osaka, Japan
Shizuoka Cancer Center; Thoracic Oncology
🇯🇵Shizuoka, Japan
National Cancer Center Hospital; Thoracic Medical Oncology
🇯🇵Tokyo, Japan
The Cancer Institute Hospital of JFCR, Respiratory Medicine
🇯🇵Tokyo, Japan
American University of Beirut - Medical Center
🇱🇧Beirut, Lebanon
Hotel Dieu de France; Oncology
🇱🇧Beirut, Lebanon
Middle East Inst. of Health; Oncology
🇱🇧Beirut, Lebanon
Centenario Hospital Miguel Hidalgo
🇲🇽Aguascalientes, Mexico
Hospital Central Sur de Alta Especialidad Petróleos Mexicanos
🇲🇽Mexico City, Mexico
Centro Médico Abc the American British Cowdray Medical Center, I.A.P. - Centro de Cáncer
🇲🇽Mexico City, Mexico
Amphia Ziekenhuis; Afdeling Longziekten
🇳🇱Breda, Netherlands
Leyenburg Hospital; Pulmonology
🇳🇱Den Haag, Netherlands
Ziekenhuis St Jansdal; Dept of Lung Diseases
🇳🇱Harderwijk, Netherlands
Catharina Ziekenhuis; Dept of Lung Diseases
🇳🇱Eindhoven, Netherlands
Academisch Ziekenhuis Maastricht
🇳🇱Maastricht, Netherlands
Antonius Ziekenhuis; Dept of Lung Diseases
🇳🇱Nieuwegein, Netherlands
College of Medicine & Sciences, Sultan Qaboos University Hospital
🇴🇲Muscat, Oman
Fnsp Fdr Banska Bystrica; Dep of Pneumology&Ftizeology
🇸🇰Banska Bystrica, Slovakia
FNsP Bratislava, Nemocnica Ruzinov
🇸🇰Bratislava, Slovakia
Inst. of Tb & Respiratory Diseases; Dep. of Oncology
🇸🇰Nitra, Slovakia
Vychodoslovensky onkologicky ustav
🇸🇰Kosice, Slovakia
Hospital de Cruces; Servicio de Oncologia
🇪🇸Barakaldo, Vizcaya, Spain
Hospital General Univ. de Alicante; Servicio de Oncologia
🇪🇸Alicante, Spain
Hospital Universitario Clínico San Carlos; Servicio de Oncologia
🇪🇸Madrid, Spain
Centro Oncologico MD Anderson International Espana
🇪🇸Madrid, Spain
Hospital Universitario La Paz; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
🇪🇸Valencia, Spain
Hospital Universitario Dr. Peset; Servicio de Oncologia
🇪🇸Valencia, Spain
Hospital Universitario Miguel Servet; Servicio Oncologia
🇪🇸Zaragoza, Spain
Tawam Hospital; Medical Oncology Department
🇦🇪Al Ain, United Arab Emirates
St. Francis Medical Group
🇺🇸Indianapolis, Indiana, United States
Tufts Medical Center; Neely Cancer Center
🇺🇸Boston, Massachusetts, United States
Mid Ohio Onc Hematology Inc
🇺🇸Columbus, Ohio, United States
Cancer Center of Kansas
🇺🇸Wichita, Kansas, United States
Nordsjællands Hospital, Hillerød, Onkologisk Afdeling
🇩🇰Hillerod, Denmark
Sutter Cancer Center
🇺🇸Sacramento, California, United States
Ann Arbor Hematology Oncology
🇺🇸Ann Arbor, Michigan, United States
Henry Ford Hospital; Hematology Oncology
🇺🇸Detroit, Michigan, United States
Jewish Cancer Care
🇺🇸Louisville, Kentucky, United States
Bay Area Hospital
🇺🇸Coos Bay, Oregon, United States
Hospital Sao Jose
🇧🇷São Paulo, SP, Brazil